CordenPharma Opens Drug Product Innovation Centre of Excellence with the Addition of Bioavailability Enhancement

April 23, 2023
CordenPharma Opens Early Phase Drug Product Innovation Centre of Excellence with Bioavailability Enhancement Technologies.

CordenPharma Opens Early Phase Drug Product Innovation Centre of Excellence with the Addition of Bioavailability Enhancement Technologies

CordenPharma’s Drug Product Innovation Centre of Excellence in CordenPharma Plankstadt (DE).

CordenPharma is pleased to announce the opening of a Drug Product Innovation Centre of Excellence with new Bioavailability Enhancement capabilities for the manufacturing of Oral Solid Dosage (OSD) Drug Products that contain low bioavailability APIs at our CordenPharma Plankstadt facility located near Heidelberg, Germany.

These new Bioavailability Enhancement capabilities were added in response to our customers’ demands and the recognition of gaps in formulation technologies for solubility-challenged APIs. Already equipped with conventional small scale OSD development processes including blending, granulation, compression, coating, and a tablet simulator, CordenPharma’s Drug Product Innovation Centre has added spray drying, hot melt extrusion, nanomilling, and micronization technologies. In addition, utilization of Lipid Excipients integrated from our Lipids Platform in SEDDS/SMEDDS formulations can address permeability issues. The Centre is capable of handling multiple projects in parallel, with open capacity to start projects immediately.

“This is an extremely important and significant investment for CordenPharma’s Oral Solid Dose capabilities. Our goal is to be the leading CDMO for the development and manufacturing of highly potent and non-potent solid dosage forms. Adding these enabling technologies to our toolbox allows us to help more customers that have bioavailability challenges with solubility-limited APIs. We are excited about this investment in Plankstadt, as it strengthens our core capabilities and expands our service offerings,” states Dr. Brittany Hayes, Director of CordenPharma’s Global Highly Potent & Oncology Platform.

“This is an extremely important and significant investment for CordenPharma’s Oral Solid Dose capabilities. Our goal is to be the leading CDMO for the development and manufacturing of highly potent and non-potent solid dosage forms. Adding these enabling technologies to our toolbox allows us to help more customers that have bioavailability challenges with solubility-limited APIs. We are excited about this investment in Plankstadt, as it strengthens our core capabilities and expands our service offerings,” states Dr. Brittany Hayes, Director of CordenPharma’s Global Highly Potent & Oncology Platform.

Contact Us for more information on Bioavailability Enhancement of solubility-challenged APIs for OSD Drug Product manfucturing.

Name	_ga
Provider	google-analytics.com
Purpose	This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.
Cookie life cycle	2 years

Name	_gid
Provider	google-analytics.com
Purpose	This cookie is set by Google Analytics. It stores and update a unique value for each page visited and is used to count and track pageviews.
Cookie life cycle	1 Day

Name	collect
Provider	google-analytics.com
Purpose	"Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
Cookie life cycle	session

Name	vuid
Provider	vimeo.com
Purpose	Collects data on the user's visits to the website, such as which pages have been read. These cookies are used by the Vimeo video player on websites.
Cookie life cycle	2 years

Name	BE_CLA3
Provider	BrightEdge
Purpose	Enables data aggregation, analysis and report creation to assess marketing effectiveness and for website performance.
Cookie life cycle	37199 days

Essential

Statistics

Marketing

Name	__utmc
Provider	google-analytics.com
Purpose	This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. It is not used in most sites but is set to enable interoperability with the older version of Google Analytics code known as Urchin. In this older versions this was used in combination with the __utmb cookie to identify new sessions/visits for returning visitors. When used by Google Analytics this is always a Session cookie which is destroyed when the user closes their browser. Where it is seen as a Persistent cookie it is therefore likely to be a different technology setting the cookie.
Cookie life cycle	Session

Name	__utmt
Provider	google-analytics.com
Purpose	This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie determines new sessions and visits and expires after 30 minutes. The cookie is updated every time data is sent to Google Analytics. Any activity by a user within the 30 minute life span will count as a single visit, even if the user leaves and then returns to the site. A return after 30 minutes will count as a new visit, but a returning visitor.
Cookie life cycle	30 minutes

Name	Google Maps API
Provider	Google Maps
Purpose	to read user IP address.
Cookie life cycle	expires immediately

Name	GPS
Provider	Youtube
Purpose	YouTube is a Google owned platform for hosting and sharing videos. YouTube collects user data through videos embedded in websites, which is aggregated with profile data from other Google services in order to display targeted advertising to web visitors across a broad range of their own and other websites.
Cookie life cycle	session